1. Home
  2. BRCB vs ELTX Comparison

BRCB vs ELTX Comparison

Compare BRCB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRCB

Black Rock Coffee Bar Inc.

HOLD

Current Price

$8.16

Market Cap

206.8M

Sector

N/A

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.95

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRCB
ELTX
Founded
2008
2011
Country
United States
United States
Employees
2800
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.8M
185.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BRCB
ELTX
Price
$8.16
$2.95
Analyst Decision
Buy
Strong Buy
Analyst Count
7
3
Target Price
$24.83
$18.00
AVG Volume (30 Days)
399.9K
4.0M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
$30.74
N/A
Revenue Next Year
$24.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.11
$2.66
52 Week High
$30.40
$16.00

Technical Indicators

Market Signals
Indicator
BRCB
ELTX
Relative Strength Index (RSI) 51.60 34.70
Support Level $7.15 $2.72
Resistance Level $8.79 $9.76
Average True Range (ATR) 0.56 0.48
MACD 0.09 0.15
Stochastic Oscillator 59.15 5.85

Price Performance

Historical Comparison
BRCB
ELTX

About BRCB Black Rock Coffee Bar Inc.

Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: